SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
KISNER DANIEL L

(Last) (First) (Middle)
C/O TEKMIRA PHARMACEUTICALS CORP.
SUITE 100, 8900 GLENLYON PARKWAY

(Street)
BURNABY A1 V5J 5J8

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2015
3. Issuer Name and Ticker or Trading Symbol
TEKMIRA PHARMACEUTICALS Corp [ TKMR ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares 12,500 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (Right to Buy) 01/28/2010 01/27/2020 Common Shares 10,000 3.85(1) D
Director Stock Option (Right to Buy) 08/10/2011 08/09/2021 Common Shares 5,000 2.4(1) D
Director Stock Option (Right to Buy) 12/27/2011 12/22/2021 Common Shares 5,000 1.7(1) D
Director Stock Option (Right to Buy) 12/10/2012 12/09/2022 Common Shares 5,000 5.15(1) D
Director Stock Option (Right to Buy) 05/08/2014 05/07/2024 Common Shares 17,500 12.52(1) D
Warrants 06/16/2011 06/16/2016 Common Shares 5,000 3.35(1) D
Warrants 02/29/2012 03/01/2017 Common Shares 1,250 2.6(1) D
Explanation of Responses:
1. Expressed in Canadian dollars.
Remarks:
/s/ Daniel L. Kisner 12/31/2014
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.